Download White Paper

Terms and Conditions  |  Privacy Policy

† You may still receive emails from us regarding any current registrations or orders.

Biotech Week Boston

Through the last two decades, a phenomenal evolution of bispecific antibodies has developed in front of our eyes, with this “zoo” of bispecificity being populated by many different species: there are small molecules made exclusively of the antigenbinding sites of two antibodies; molecules with an Immunoglobulin G (IgG) structure; and, large complex molecules composed of different antigen-binding moieties, often combined with dimerization modules.

This whitepaper looks at:

  • Latest industry developments, discoveries and investment in bispecific antibodies
  • Emerging bispecific technologies/modes of action
  • Current challenges facing (pre-)clinical development
  • Discovery strategies
  • Bispecific target discovery, identification and validation strategies.